Status:
COMPLETED
Myfortic Conversion Trial in OLT Recipients With GI Intolerance
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
GI Disturbance
Eligibility:
All Genders
18-75 years
Brief Summary
Liver transplant patients often require multimodal immunosuppressive therapy to minimize their risk for rejection. In our regimen, MMF (mycophenolate mofetil) is often added to lower the side effects ...
Eligibility Criteria
Inclusion
- Recipients of orthotopic liver transplant at least 8 weeks post transplant
- Mild and/or moderate GI complaints directly related to MMF
Exclusion
- Multi-organ transplant recipients
- Evidence of graft rejection within 14 days prior to Baseline visit
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00619216
Start Date
March 1 2008
End Date
December 1 2009
Last Update
June 3 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of North Carolina-Chapel Hill
Chapel Hill, North Carolina, United States, 27599-7211